GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Other Operating Expense

Pharmaron Beijing Co (SZSE:300759) Other Operating Expense : ¥851 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Other Operating Expense?

Pharmaron Beijing Co's Other Operating Expense for the three months ended in Mar. 2024 was ¥12 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was ¥851 Mil.

Pharmaron Beijing Co's quarterly Other Operating Expense increased from Sep. 2023 (¥-429 Mil) to Dec. 2023 (¥836 Mil) but then declined from Dec. 2023 (¥836 Mil) to Mar. 2024 (¥12 Mil).

Pharmaron Beijing Co's annual Other Operating Expense increased from Dec. 2021 (¥592 Mil) to Dec. 2022 (¥766 Mil) and increased from Dec. 2022 (¥766 Mil) to Dec. 2023 (¥838 Mil).


Pharmaron Beijing Co Other Operating Expense Historical Data

The historical data trend for Pharmaron Beijing Co's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Other Operating Expense Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 271.96 345.31 591.84 766.00 837.97

Pharmaron Beijing Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.73 432.48 -429.01 836.23 11.59

Pharmaron Beijing Co Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥851 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaron Beijing Co Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co (SZSE:300759) Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.
Executives
Lou Xiao Qiang Directors, executives
Zheng Bei Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines